Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics announced an amendment disclosing the counterparty of a 2023 contract manufacturing LOI as ‘Kiniksa Pharmaceuticals (UK), Ltd’ following the execution of the main contract.
📊 [Key Disclosure Details & Summary Statistics]
- Disclosure Type: Correction Report (Original Disclosure Date: 2023-05-30)
- Reason for Correction: Disclosure of previously non-disclosed details following the execution of the main contract with the client
- Corrected Item (Counterparty):
- Counterparty: (Before) Pharmaceutical company located in Europe → (After) Kiniksa Pharmaceuticals (UK), Ltd
- Summary of Original Disclosure (Execution of Contract Manufacturing LOI):
- Counterparty: Kiniksa Pharmaceuticals (UK), Ltd
- Contract Amount: KRW 107,513,583,360 (KRW ~107.5B) / USD 81,105,600
- Contract Ratio to Recent Annual Revenue: 3.58% (Based on 2022 annual revenue of KRW 3,001,295,197,683)
- LOI Execution Date: May 30, 2023
- Board Resolution Date or Fact Confirmation Date: May 30, 2023
- Other Key Investment Matters:
- The contract amount was converted using the initial FX rate of USD/KRW 1,325.60 on May 30, 2023, based on the confirmed amount of USD 81,105,600.
- The agreement is legally binding between both parties, and definitive details will be disclosed upon execution of the main contract.
- The contract period is from the date of LOI execution until the execution of the main contract.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Main Contract Execution and Confirmed Terms
This amendment reveals the previously undisclosed counterparty, Kiniksa Pharmaceuticals, as a result of finalizing the definitive main contract. Reviewing the official sales/supply contract disclosure for the main agreement to check confirmed values, contract duration, and any term adjustments compared to the initial LOI is important for understanding how this order translates into financial performance. Relevant details can be verified through related contract disclosures or subsequent periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
